Indian drugmakers face squeeze in US on fears of tougher rules

17 March, 2017

India’s small and medium-sized generic drugmakers say the threat of tougher rules and higher barriers for outsiders in the U.S. healthcare market will force many to find a niche or focus their expansion efforts on other countries.

India supplies nearly a third of medicines sold in the United States, the world’s largest healthcare market. Cut-price generics sold by India’s small- and medium-sized drugmakers have been critical in bringing down prices there.

A more protectionist stance by President Donald Trump, with the prospect of import tariffs and the U.S. boosting local drug manufacturing, mean the operating environment for smaller generic players will get worse, executives at Indian companies said.

“If the challenges keep increasing, competition will reduce, and this could actually increase prices there,” said D.G. Shah, secretary general of the Indian Pharmaceutical Association, which represents 20 large Indian drugmakers.

J. Jayaseelan, who owns Nuray Chemicals, a maker of drug ingredients, said many Indian firms are reconsidering, or putting on hold, U.S. expansion plans.

Ajanta Pharma is one such firm. The mid-sized generics drug maker said it had no plans to scale up its U.S. business and would invest more in Asia and Africa instead.

“It’s not a major market for us right now … you’ve got to look at the risk-reward ratio,” said Rajeev Agarwal, general manager of finance at Ajanta.

The risks comes as U.S. revenue growth for these firms is falling. U.S. revenues for Indian drugmakers rose 15 percent in 2016, half the average annual growth rate of 33 percent between 2011 and 2015, ratings agency ICRA said. It expects the growth rate to fall further this year.

Consolidation among U.S. drugs distributors and a federal investigation into drug pricing have also reduced the pricing power of drugsmakers.

The U.S. drugs regulator, the Food and Drug Administration, has also banned dozens of Indian drug factories from supplying the U.S. market following inspections that found inadequate quality-control practices. Companies have invested significant sums to raise their quality standards.

Like this report? Sign up for our daily newsletter to get our top reports.

Leave Your Comment
US bans Divi's Laboratories factory; shares hit three-year low

US bans Divi’s Laboratories factory; shares hit three-year low

Reuters 3 months ago
U.S. health regulators have banned a drug production site in India belonging to Divi’s Laboratories Ltd due to manufacturing violations, sending the company’s shares down...
Cadila slapped with US FDA warning on two facilities

Cadila slapped with US FDA warning on two facilities

Joseph Rai 1 year ago
Shares of drugmaker Cadila Healthcare Ltd plunged as much as 15 per cent in intra-day trade on Thursday after the US Food and Drug Administration...
Roche gives up on India patent for breast cancer drug

Roche gives up on India patent for breast cancer drug

Reuters 4 years ago
Roche Holding AG has decided not to pursue a patent application for its breast cancer drug Herceptin in India, the Swiss company said on Friday,...
No Comments

Indian drugmakers face squeeze in US on fears of tougher rules

Powered by VIP